{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:49:39Z","timestamp":1791866979279,"version":"4.3.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2012,6,13]],"date-time":"2012-06-13T00:00:00Z","timestamp":1339545600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s11606-012-2098-1","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T16:42:35Z","timestamp":1339519355000},"page":"1697-1703","source":"Crossref","is-referenced-by-count":30,"title":["Linking Drugs to Obscure Illnesses: Lessons from Pure Red Cell Aplasia, Nephrogenic Systemic Fibrosis, and Reye\u2019s Syndrome. A Report From the Southern Network on Adverse Reactions (SONAR)"],"prefix":"10.1007","volume":"27","author":[{"given":"Charles L.","family":"Bennett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Starko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik S.","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Cowper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain C.","family":"Macdougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaina P.","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Brandon","family":"Bookstaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LeAnn B.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudha","family":"Xirasagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Trenery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanna","family":"Murday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Luminari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Cournoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald R.","family":"Mattison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,6,13]]},"reference":[{"key":"2098_CR1","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.287.17.2215","volume":"287","author":"KE Lasser","year":"2002","unstructured":"Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287:2215\u201320.","journal-title":"JAMA"},{"key":"2098_CR2","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(00)02694-5","volume":"356","author":"SE Cowper","year":"2000","unstructured":"Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000\u20131.","journal-title":"Lancet"},{"key":"2098_CR3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0140-6736(63)90554-3","volume":"2","author":"RDK Reye","year":"1963","unstructured":"Reye RDK, Morgan G, Baral J. Encephalopathy and fatty degeneration of the viscera. A disease entity in childhood. Lancet. 1963;2:749\u201352.","journal-title":"Lancet"},{"key":"2098_CR4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJMoa011931","volume":"346","author":"N Casadevall","year":"2002","unstructured":"Casadevall N, Nataf J, Viron B, et al. Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469\u201375.","journal-title":"N Engl J Med"},{"key":"2098_CR5","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1681\/ASN.2006060601","volume":"17","author":"P Marckmann","year":"2006","unstructured":"Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359\u201362.","journal-title":"J Am Soc Nephrol"},{"key":"2098_CR6","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1542\/peds.66.6.859","volume":"66","author":"KM Starko","year":"1980","unstructured":"Starko KM, Ray GC, Dominguez LB, Stromberg WL, Woodall DF. Reye's syndrome and salicylate use. Pediatrics. 1980;66:859\u201364.","journal-title":"Pediatrics"},{"issue":"14","key":"2098_CR7","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1056\/NEJMoa040528","volume":"351","author":"CL Bennett","year":"2004","unstructured":"Bennett CL, Luminari S, Nissenson AR, et al. Pure Red-cell aplasia and epoetin therapy. New Engl J Med. 2004;351(14):1403\u20131408.","journal-title":"New Engl J Med"},{"key":"2098_CR8","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jama.1913.04340130005003","volume":"60","author":"PJ Hanzlik","year":"1913","unstructured":"Hanzlik PJ. A study of the toxicity of the salicylates based on clinical statistics. JAMA. 1913;60:957\u2013962.","journal-title":"JAMA"},{"key":"2098_CR9","volume-title":"The diseases of infancy and childhood. Designed for use of students and practitioners of medicine","year":"1918","unstructured":"Koplik H, ed. The diseases of infancy and childhood. Designed for use of students and practitioners of medicine. Philadelphia: Lea and Febiger; 1918."},{"key":"2098_CR10","volume-title":"The diseases of infancy and childhood. For the use of students and practitioners of medicine","year":"1920","unstructured":"Holt LE, Howland J, eds. The diseases of infancy and childhood. For the use of students and practitioners of medicine. New York: D. Appleton and Company; 1920."},{"key":"2098_CR11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0022-3476(47)80027-7","volume":"30","author":"JA Erganian","year":"1947","unstructured":"Erganian JA, Forbes GB, Case DM. Salicylate intoxication in the infant and young child. J Pediatr. 1947;30:129\u201345.","journal-title":"J Pediatr"},{"key":"2098_CR12","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0022-3476(54)80002-3","volume":"44","author":"K Bain","year":"1954","unstructured":"Bain K. Death due to accidental poisoning in young children. J Pediatr. 1954;44:616\u201323.","journal-title":"J Pediatr"},{"key":"2098_CR13","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1542\/peds.18.4.578","volume":"18","author":"HD Riley Jr","year":"1956","unstructured":"Riley HD Jr, Worley L. Salicylate intoxication. Pediatrics. 1956;18:578\u201394.","journal-title":"Pediatrics"},{"key":"2098_CR14","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJM195812182592501","volume":"259","author":"WE Segar","year":"1958","unstructured":"Segar WE, Holliday MA. Physiologic abnormalities of salicylate intoxication. N Engl J Med. 1958;259:1191\u201398.","journal-title":"N Engl J Med"},{"key":"2098_CR15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(00)97557-3","volume":"1","author":"WR Brain","year":"1929","unstructured":"Brain WR, Hunter D, Turnbull HM. Acute meningo-encephalomyelitis of childhood. Lancet. 1929;1:221\u20137.","journal-title":"Lancet"},{"key":"2098_CR16","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1056\/NEJM197112092852402","volume":"285","author":"JC Partin","year":"1971","unstructured":"Partin JC, Schubert WK, Partin JS. Mitochondrial ultrastructure in Reye\u2019s syndrome (encephlalopathy and fatty degeneration of the viscera). N Engl J Med. 1971;285:1339\u201343.","journal-title":"N Engl J Med"},{"key":"2098_CR17","first-page":"583","volume":"103","author":"EA Mortimer","year":"1962","unstructured":"Mortimer EA, Lepow M. Varicella with hypoglycemia possibly due to salicylates. Am J Dis Child. 1962;103:583\u201390.","journal-title":"Am J Dis Child"},{"key":"2098_CR18","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(65)91362-0","volume":"1","author":"HM Giles","year":"1965","unstructured":"Giles HM. Letter to the Editor: encephalopathy and fatty degeneration of the viscera. Lancet. 1965;1:1075.","journal-title":"Lancet"},{"key":"2098_CR19","first-page":"435","volume":"73","author":"AF Coburn","year":"1943","unstructured":"Coburn AF. Salicylate therapy in acute rheumatic fever. Bull J Hopkins Hosp. 1943;73:435\u201364.","journal-title":"Bull J Hopkins Hosp"},{"key":"2098_CR20","first-page":"153","volume":"17","author":"JDP Graham","year":"1948","unstructured":"Graham JDP, Parker WA. The toxic manifestations of sodium salicylate therapy. Quart J Med. 1948;17:153\u201363.","journal-title":"Quart J Med"},{"key":"2098_CR21","first-page":"35345","volume":"42","author":"Food and Drug Administration","year":"1977","unstructured":"Food and Drug Administration. Over-the-counter drugs. Establishment of a monograph for OTC internal analgesic, antipyretic and antirheumtic products. Fed Regist. 1977;42:35345\u2013621.","journal-title":"Fed Regist"},{"key":"2098_CR22","first-page":"2321","volume":"29","author":"Follow-up on Reye Syndrome-United States","year":"1980","unstructured":"Follow-up on Reye Syndrome-United States. MMWR Morb Mortal Wkly Rep. 1980;29:2321\u20132.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2098_CR23","first-page":"532","volume":"29","author":"Reye\u2019s syndrome \u2013 Ohio, Michigan","year":"1980","unstructured":"Reye\u2019s syndrome \u2013 Ohio, Michigan. MMWR Morb Mortal Wkly Rep. 1980;29:532\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2098_CR24","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1001\/jama.1982.03320470035029","volume":"247","author":"RJ Waldman","year":"1982","unstructured":"Waldman RJ, Hall WN, McGee H, Van Amburg G. Aspirin as a risk factor in Reye's syndrome. JAMA. 1982;247:3089\u201394.","journal-title":"JAMA"},{"key":"2098_CR25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.1982.03330060027028","volume":"248","author":"TJ Halpin","year":"1982","unstructured":"Halpin TJ, Holtzhauer FJ, Campbell RJ, et al. Reye's syndrome and medication use. JAMA. 1982;248:687\u201391.","journal-title":"JAMA"},{"key":"2098_CR26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0140-6736(83)91629-X","volume":"1","author":"KM Starko","year":"1983","unstructured":"Starko KM, Mullick FG. Hepatic and cerebral pathology findings in children with fatal salicylate intoxication: further evidence for a causal relation between salicylate and Reye\u2019s syndrome. Lancet. 1983;1:326\u201329.","journal-title":"Lancet"},{"key":"2098_CR27","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.1988.03410050077033","volume":"260","author":"PF Pinsky","year":"1988","unstructured":"Pinsky PF, Hurwitz ES, Schonberger LB, Gunn WJ. Reye's syndrome and aspirin. Evidence for dose\u2013response effect. JAMA. 1988;260:657\u201361.","journal-title":"JAMA"},{"key":"2098_CR28","first-page":"53","volume":"31","author":"National surveillance for Reye syndrome","year":"1982","unstructured":"National surveillance for Reye syndrome. 1981: update, Reye syndrome, and salicylate usage. MMWR Morb Mortal Wkly Rep. 1982;31:53\u201361.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2098_CR29","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1542\/peds.69.6.810","volume":"69","author":"Committee on Infectious Diseases","year":"1982","unstructured":"Committee on Infectious Diseases. Aspirin and Reye\u2019s syndrome. Pediatrics. 1982;69:810\u201312.","journal-title":"Pediatrics"},{"issue":"22","key":"2098_CR30","first-page":"289","volume":"31","author":"Centers for Disease Control (CDC)","year":"1982","unstructured":"Centers for Disease Control (CDC). Surgeon General\u2019s advisory on the use of salicylates and Reye syndrome. MMWR Morb Mortal Wkly Rep. 1982;31(22):289\u2013294.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2098_CR31","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1056\/NEJM198510033131403","volume":"313","author":"ES Hurwitz","year":"1985","unstructured":"Hurwitz ES, Barrett MJ, Bregman D, et al. Public Health Service study on Reye's syndrome and medications. Report of the pilot phase. N Engl J Med. 1985;313:849\u201357.","journal-title":"N Engl J Med"},{"key":"2098_CR32","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1001\/jama.1987.03390140075030","volume":"257","author":"ES Hurwitz","year":"1987","unstructured":"Hurwitz ES, Barrett MJ, Bregman D, et al. Public Health Service study of Reye's syndrome and medications: report of the main study. JAMA. 1987;257:1905\u201311.","journal-title":"JAMA"},{"key":"2098_CR33","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1001\/jama.1989.03420170061031","volume":"261","author":"BW Forsyth","year":"1989","unstructured":"Forsyth BW, Horwitz RI, Acampora D, et al. New epidemiologic evidence confirming that bias does not explain the aspirin\/Reye\u2019s syndrome association. JAMA. 1989;261:2517\u201324.","journal-title":"JAMA"},{"key":"2098_CR34","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2165\/00002018-200629120-00003","volume":"29","author":"JFT Glasgow","year":"2006","unstructured":"Glasgow JFT. Reye\u2019s syndrome: the case for a causal link. Drug Saf. 2006;29:1111\u20131121.","journal-title":"Drug Saf"},{"key":"2098_CR35","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1542\/peds.79.6.858","volume":"79","author":"JB Arrowsmith","year":"1987","unstructured":"Arrowsmith JB, Kennedy DL, Kuritsky JN, Faich GA. National patterns of aspirin use and Reye syndrome reporting, United States, 1980\u20131985. Pediatrics. 1987;79:858\u201363.","journal-title":"Pediatrics"},{"key":"2098_CR36","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJM199905063401801","volume":"340","author":"ED Belay","year":"1999","unstructured":"Belay ED, Bresee JSA, Holman RC, Khan AS, Shahriari A, Schonberger L. Reye's syndrome in the United States from 1981 through 1997. N Engl J Med. 1999;340:1377\u201382.","journal-title":"N Engl J Med"},{"key":"2098_CR37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/ckj\/sfr172","volume":"5","author":"CL Bennett","year":"2012","unstructured":"Bennett CL, Qureshi ZP, Sartor AO, Norris LB, Murday A, Xirasagar S, Thomsen HS. Gadolinium induced nephrogrenic systemic fibrosis, the rise and fall of an iatrogenic disease. Clin Kidney J. 2012;5:82\u201388.","journal-title":"Clin Kidney J"},{"key":"2098_CR38","unstructured":"Transcript of Hearings on Gadolinium-based Contrast Media Agents. Joint Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM197768.pdf (Accessed 4\/6\/2012)"},{"key":"2098_CR39","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2005.09.005","volume":"35","author":"SE Cowper","year":"2006","unstructured":"Cowper SE, Bucala R, Leboit PE. Nephrogenic fibrosing dermopathy\/nephrogenic systemic fibrosis\u2013setting the record straight. Semin Arthritis Rheum. 2006;35:208\u201310.","journal-title":"Semin Arthritis Rheum"},{"key":"2098_CR40","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1093\/ndt\/gfm261","volume":"22","author":"P Marckmann","year":"2007","unstructured":"Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case\u2013control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2007;22:3174\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"2098_CR41","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejrad.2008.01.032","volume":"66","author":"P Marckmann","year":"2008","unstructured":"Marckmann P. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital. Eur J Radiol. 2008;66:187\u201390.","journal-title":"Eur J Radiol"},{"key":"2098_CR42","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.rcl.2009.05.004","volume":"47","author":"P Marckmann","year":"2009","unstructured":"Marckmann P, Skov L. Nephrogenic systemic fibrosis: clinical picture and treatment. Radiol Clin North Am. 2009;47:833\u201340.","journal-title":"Radiol Clin North Am"},{"key":"2098_CR43","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/ndt\/gfk062","volume":"21","author":"T Grobner","year":"2006","unstructured":"Grobner T. Gadolinium\u2013a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"2098_CR44","unstructured":"Influence of human proteins on the relaxivity of gadolinium complexes at http:\/\/www.b.dk\/upload\/webred\/bmsandbox\/uploads\/2012\/03\/bb81a28663015b7a1d828ee723de7a26.pdf (accessed 4\/6\/2012)"},{"key":"2098_CR45","unstructured":"FDA: New warnings required on use of gadolinium-based contrast agents. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm225286.htm (accessed 4\/6\/2012)."},{"key":"2098_CR46","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.rcl.2009.05.003","volume":"47","author":"HS Thomsen","year":"2009","unstructured":"Thomsen HS. Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin North Am. 2009;47:827\u201331.","journal-title":"Radiol Clin North Am"},{"key":"2098_CR47","unstructured":"Lawyer Inquiry Concerning Omniscan (Advokatunders\u00f8gelse Vedr\u00f8rende Omniscan). http:\/\/sum.dk\/Aktuelt\/Nyheder\/Medicin\/2010\/November\/\u223c\/media\/Filer%20-%20dokumenter\/Omniscan-nov-2010\/Omniscan-nov-2010.ashx (Accessed 4\/6\/2012)"},{"key":"2098_CR48","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejrad.2008.02.009","volume":"66","author":"DI Stenver","year":"2008","unstructured":"Stenver DI. Pharmacovigilance: what to do if you see an adverse reaction and the consequences. Eur J Radiol. 2008;66:184\u20136.","journal-title":"Eur J Radiol"},{"key":"2098_CR49","unstructured":"The Danish Medicines Agency Report on Omniscan, March 2008. 2008. http:\/\/s3.amazonaws.com\/propublica\/assets\/omniscan\/010408_FULL_Report_from_DMA.pdf (Accessed 4\/6\/2012)"},{"key":"2098_CR50","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1097\/01.ASN.0000140219.28618.9F","volume":"15","author":"D Cournoyer","year":"2004","unstructured":"Cournoyer D, Toffelmire EB, Wells GA, et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol. 2004;15:2728\u201334.","journal-title":"J Am Soc Nephrol"},{"key":"2098_CR51","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood-2005-02-0508","volume":"106","author":"CL Bennett","year":"2005","unstructured":"Bennett CL, Cournoyer D, Carson KR, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2005;106:3343\u20137.","journal-title":"Blood"},{"key":"2098_CR52","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1056\/NEJMoa074037","volume":"361","author":"IC Macdougall","year":"2009","unstructured":"Macdougall IC, Rossert J, Casadevall N, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med. 2009;361:1848\u201355.","journal-title":"N Engl J Med"},{"key":"2098_CR53","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1111\/j.1523-1755.2005.00340.x","volume":"67","author":"K Boven","year":"2005","unstructured":"Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 2005;67:2346\u201353.","journal-title":"Kidney Int"},{"key":"2098_CR54","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/MNH.0b013e3283309660","volume":"18","author":"MA Perazella","year":"2009","unstructured":"Perazella MA. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm. Curr Opin Nephrol Hypertens. 2009;18:519\u20132556.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"8","key":"2098_CR55","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1111\/j.1537-2995.2008.01749.x","volume":"48","author":"JM McKoy","year":"2008","unstructured":"McKoy JM, Stonecash RE, Cournoyer D, Rossert J, Nissenson AR, Raisch DW, Casadevall N, Bennett CL. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008;48(8):1754\u201362. Epub 2008 May 14.","journal-title":"Transfusion"},{"key":"2098_CR56","doi-asserted-by":"crossref","unstructured":"Macdougall IC, Roger SD, de Francisco A, Goldsmith DJ, Schellekens H, Ebbers H, Jelkmann W, London G, Casadevall N, H\u00f6rl WH, Kemeny DM, Pollock C. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int. 2012, Feb 15. [Epub ahead of print]","DOI":"10.1038\/ki.2011.500"},{"key":"2098_CR57","doi-asserted-by":"crossref","unstructured":"Seidl A, Hainzl O, Richter M, Fischer R, B\u00f6hm S, Deutel B, Hartinger M, Windisch J, Casadevall N, London GM, Macdougall I. Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of Immunogenicity. Pharm Res. 2011 Nov 18. [Epub ahead of print]","DOI":"10.1007\/s11095-011-0621-4"},{"issue":"1","key":"2098_CR58","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5414\/CN107304","volume":"77","author":"M Haag-Weber","year":"2012","unstructured":"Haag-Weber M, Eckardt KU, H\u00f6rl WH, Roger SD, Vetter A, Roth K. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin alfa (HX575) in non-dialysis patients with renal anaemia: a multi-centre, randomised, double-blind study. Clin Nephrol. 2012;77(1):8\u201317.","journal-title":"Clin Nephrol"},{"key":"2098_CR59","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/0140-6736(92)93058-U","volume":"340","author":"DE Davis","year":"1992","unstructured":"Davis DE, Buffler P. Reduction of deaths after drug labeling for risk of Reye\u2019s syndrome. Lancet. 1992;340:1042.","journal-title":"Lancet"},{"key":"2098_CR60","unstructured":"EPI News Brief. http:\/\/www.epimonitor.net\/epimonday\/previousissues\/02-09-09.htm (accessed 5\/31\/2011)"},{"key":"2098_CR61","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1126\/science.328.5984.1348","volume":"328","author":"T Wogan","year":"2010","unstructured":"Wogan T. Scientific publishing. A chilling effect? Science. 2010;328:1348\u20139. 51.","journal-title":"Science"},{"key":"2098_CR62","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJM198307213090302","volume":"309","author":"PK Lichtenstein","year":"1983","unstructured":"Lichtenstein PK, Heubi JE, Daugherty CC, et al. A frequent cause of vomiting and liver dysfunction after varicella and upper respiratory tract infection. N Eng J Med. 1983;309:133\u201339.","journal-title":"N Eng J Med"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-012-2098-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11606-012-2098-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-012-2098-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T19:47:29Z","timestamp":1642448849000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11606-012-2098-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,13]]},"references-count":62,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["2098"],"URL":"https:\/\/doi.org\/10.1007\/s11606-012-2098-1","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,13]]}}}